Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.

Rick Hermsen Esmée B C Wedick Maarten J M Vinken Ludwike W M van Kalmthout Heidi V N Küsters-Vandevelde Charlotte H W Wijers Diederik M Somford Jean-Paul A van Basten

Eur J Nucl Med Mol Imaging

Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.

Published: September 2022

F-PSMA-1007 is a radiotracer for prostate cancer staging that lacks large validation studies for its diagnostic accuracy compared to traditional methods like histopathology.
A trial evaluated 99 men with intermediate to high-risk prostate cancer, measuring the sensitivity and specificity of F-PSMA-1007 PET/CT against lymph node dissection results.
The results indicated high specificity (89.9%) but moderate sensitivity (53.3%), suggesting that while it’s effective for certain detections, it shouldn’t replace extensive surgical procedures for accurate staging.

Purpose: Fluorine-18 (F) prostate-specific membrane antigen (PSMA) 1007 (F-PSMA-1007) is a radiotracer used in prostate cancer (PCa) staging. So far, no large histopathological validation study has been conducted. The objective was to determine diagnostic accuracy of F-PSMA-1007 PET/CT compared to histopathological results of extended pelvic lymph node dissection (ePLND) in men with intermediate- or high-risk PCa.

Methods: Men with newly confirmed intermediate- or high-risk PCa were prospectively enrolled in the Molecular Imaging F-PSMA-1007 PET/CT for lymph Node sTaging in primary PCa (MINT) trial. PET/CT images were read by two nuclear medicine physicians. Diagnostic accuracy was evaluated by histopathology of template resections. Sensitivity, specificity, and positive and negative predictive values (PPV, NPV) for LNI detection of F-PSMA-1007 PET/CT were calculated.

Results: Ninety-nine men were evaluated; 30.3% showed histologically confirmed LNI. Median number of resected nodes was 22 (IQR 17-28). Patient-based sensitivity, specificity, PPV, and NPV were 53.3% (95% CI 34.3-71.7%), 89.9% (95% CI 80.2-95.8%), 69.6% (95% CI 51.2-83.3%), and 81.6% (95% CI 75.0-86.8%), respectively. Template-based sensitivity was 12.9% (95% CI 5.7-23.9%), specificity 97.7% (95% CI 96.6-98.5%), PPV 23.5% (95% CI 12.7-39.5%), and NPV 95.3% (95% CI 94.9-95.7%).

Conclusion: F-PSMA-1007 PET/CT showed high specificity but moderate to low sensitivity for LNI detection in intermediate- and high-risk PCa. It cannot replace ePLND for staging. Additional studies are needed to determine exact scan indications in lymph node staging for the primary diagnostic pathway in intermediate- or high-risk PCa.

Trial Registry: December 12, 2018, Netherlands Trial Registry, NTR7670 ( https://www.trialregister.nl/trial/7428 ).

Download full-text PDF	Source
http://dx.doi.org/10.1007/s00259-022-05827-4	DOI Listing

Publication Analysis

Top Keywords

intermediate- high-risk

lymph node

f-psma-1007 pet/ct

node staging

membrane antigen

prostate cancer

extended pelvic

node dissection

diagnostic accuracy

high-risk pca

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!